Contents

Prospective Randomized Trial Comparing Efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for Treatment of Dry Eye Syndrome Following Hematopoietic Stem Cell Transplantation

July, 2015

Clinical Trial

Prospective Randomized Trial Comparing Efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for Treatment of Dry Eye Syndrome Following Hematopoietic Stem Cell Transplantation.

Boynton GE, Raoof D, Niziol LM, Hussain M, Mian SI.

Cornea. 2015 Jul;34(7):725-32.
Full text | Metrics.

Main finding: In patients with dry eye disease following hematopoietic stem cell transplantation, there was no difference in dry eye incidence or progression between loteprednol etabonate 0.5% and cyclosporine A 0.05% at 1 year.

 

  • Purpose: To evaluate loteprednol etabonate 0.5% vs cyclosporine A 0.05% in Dry Eye Disease after hematopoietic stem cell transplantation
  • Study type: Randomized controlled Trial
  • Condition: Dry Eye Disease

Participants: ≥ 18years old undergoing hematopoietic stem cell transplantation

 

n=75 patients

 

Intervention:

 

Group 1: Loteprednol 0.5% bd starting 1 month prior to transplantation
Group 2: Cyclosporine 0.05% bd starting 1 month prior to transplantation

There was no difference in dry eye incidence or progression between loteprednol etabonate 0.5% and cyclosporine A 0.05% at 1 year.

Outcomes at 1 year Loteprednol Cyclosporine
Dry eye incidence 79% 90%
Dry eye progression 26% 38%

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed